tiprankstipranks
Trending News
More News >
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Advertisement

Cytosorbents (CTSO) AI Stock Analysis

Compare
481 Followers

Top Page

CTSO

Cytosorbents

(NASDAQ:CTSO)

Rating:46Neutral
Price Target:
$1.00
▲(12.36% Upside)
Cytosorbents' overall stock score is primarily impacted by its challenging financial performance and valuation concerns. While there are some positive aspects in sales growth and restructuring efforts, the regulatory challenges and high debt levels significantly weigh down the score.
Positive Factors
Cash Management
The company conducted an equity rights offering for gross proceeds of approximately $7.3M, resulting in a total pro forma cash position of $17.1M.
Commercial Strategy
Management plans to revamp associated rep accounts and territories in Germany to boost sales and drive strong growth by the second half of 2025.
Product Revenues
Product revenues increased by 25% year-over-year and 6% quarter-over-quarter, driven by a 28% increase in direct sales outside of Germany and a 22% increase in global distributor sales.
Negative Factors
Regulatory Challenges
The company received a denial letter from the FDA regarding the 510(k) de novo application for DrugSorb-ATR during coronary artery bypass grafting surgery.
Regulatory Uncertainty
The company has not disclosed the specific issues related to the FDA denial, making it difficult to evaluate the chances of a successful appeal.
Revenue Decline
Product revenues fell by approximately 3% year-over-year and 5% quarter-over-quarter due to falling direct sales in Germany.

Cytosorbents (CTSO) vs. SPDR S&P 500 ETF (SPY)

Cytosorbents Business Overview & Revenue Model

Company DescriptionCytosorbents Corporation (CTSO) is a medical technology company focused on developing and commercializing innovative products for critical care and cardiac surgery. The company specializes in blood purification technology, particularly through its flagship product, CytoSorb, which is designed to remove harmful substances from the bloodstream during severe inflammatory conditions. Cytosorbents operates primarily in the healthcare sector, targeting hospitals and medical facilities that require advanced treatment options for patients experiencing life-threatening conditions.
How the Company Makes MoneyCytosorbents generates revenue primarily through the sale of its CytoSorb devices and related products to hospitals and healthcare providers. The company employs a direct sales model in certain markets, while also working with distributors and partners to expand its reach. Key revenue streams include the sale of disposable CytoSorb cartridges, which are used in conjunction with the device for blood purification during critical care treatments. The company has established significant partnerships with medical institutions and research organizations, which not only enhance its product visibility but also facilitate clinical studies that can lead to broader adoption of its technologies. Additionally, Cytosorbents may explore opportunities for reimbursement from healthcare payers, further contributing to its earnings potential.

Cytosorbents Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: 0.00%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a mixed sentiment. While there are strong sales growth, successful restructuring efforts, and positive clinical data, the regulatory challenges for DrugSorb ATR and increased operating expenses pose significant concerns.
Q2-2025 Updates
Positive Updates
Product Sales Growth
Cytosorbents reported product sales of $9.6 million in Q2 2025, representing a 9% year-over-year increase and a 4% increase on a constant currency basis.
German Commercial Team Reorganization Success
The German commercial team saw a 22% year-over-year and sequential growth, indicating successful reorganization and strategic realignment.
Strong Gross Margin
Gross margin performance remained solid at approximately 71%, indicating strong operational efficiency.
Positive Data on CytoSorb for Sepsis Treatment
CytoSorb demonstrated significant reductions in severe CABG-related bleeding and large transfusion events in clinical settings, strengthening its clinical utility.
Net Income Achievement
The company reported a net income of $1.9 million for Q2 2025, compared to a net loss of $4.3 million in the prior year.
Negative Updates
Regulatory Challenges for DrugSorb ATR
The FDA issued a denial letter for the de novo request for DrugSorb ATR, and Health Canada issued a notice of refusal, leading to ongoing appeals processes.
Operating Expenses Increase
Q2 operating expenses were $10.4 million, up approximately 3% from the prior year, due to unique operating and strategic charges.
Adjusted Net Loss
The adjusted net loss for the quarter was $3.7 million, compared to $2.8 million in the prior year, indicating ongoing financial pressures.
Company Guidance
In the second quarter of 2025, Cytosorbents Corp reported product sales of $9.6 million, reflecting a 9% year-over-year increase and a 4% increase on a constant currency basis. The company's gross margin held steady at approximately 71%, although there was a slight decline from the previous year's 73.5%, attributed primarily to inventory write-offs. The German commercial team saw notable improvements, with a 22% growth year-over-year and sequentially, contributing to the overall performance. Operating expenses increased slightly due to unique strategic charges, but the company remains focused on reducing core business operating costs to drive towards breakeven by the end of the year. Cytosorbents also reported a net income of $1.9 million for the quarter, but when adjusted for currency changes and non-cash items, the adjusted net loss was $3.7 million. The company continues to prepare for a potential North American launch of DrugSorb ATR, anticipating regulatory decisions from both the FDA and Health Canada by the end of 2025.

Cytosorbents Financial Statement Overview

Summary
Cytosorbents faces significant financial challenges, including declining revenues, persistent losses, and increased financial leverage. While there are slight improvements in cash flow management, the company remains unprofitable with high debt levels. Continued focus on cost management and revenue growth is essential to improve financial stability and performance.
Income Statement
45
Neutral
Cytosorbents has experienced declining revenue over the past year, with a revenue decrease from $36.35M in 2023 to $35.59M in 2024. The gross profit margin improved slightly, indicating better cost management, but the company continues to operate at a loss with a negative net profit margin of -58.2% in 2024. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.
Balance Sheet
40
Negative
The balance sheet shows a concerning increase in debt levels, with total debt rising to $26.89M in 2024. The debt-to-equity ratio has increased significantly due to declining equity, indicating higher financial leverage and potential risk. The equity ratio has decreased, suggesting reduced financial stability. Return on equity remains negative, reflecting continued unprofitability.
Cash Flow
50
Neutral
The cash flow statement highlights a reduction in negative free cash flow, from -$22.59M in 2023 to -$14.71M in 2024, indicating some improvement in cash management. However, the operating cash flow remains negative, and the company continues to rely on financing activities to support operations. The free cash flow to net income ratio is unfavorable, reflecting ongoing cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue33.48M35.59M31.08M29.36M40.11M39.45M
Gross Profit24.30M25.13M21.95M15.40M29.06M28.40M
EBITDA-16.49M-19.26M-27.88M-32.77M-21.62M-9.71M
Net Income-9.75M-20.72M-29.25M-32.81M-24.56M-7.84M
Balance Sheet
Total Assets47.99M47.37M52.96M63.23M89.52M89.95M
Cash, Cash Equivalents and Short-Term Investments10.20M3.28M14.13M22.14M52.14M71.42M
Total Debt27.06M26.89M18.31M18.25M13.82M1.03M
Total Liabilities36.40M36.26M29.48M27.86M26.94M10.73M
Stockholders Equity11.59M11.11M23.48M35.38M62.58M79.22M
Cash Flow
Free Cash Flow-10.29M-14.71M-22.59M-34.69M-18.29M-7.29M
Operating Cash Flow-9.78M-14.43M-21.66M-28.23M-14.01M-5.61M
Investing Cash Flow-601.55K-669.43K-936.24K-6.46M-4.28M-1.68M
Financing Cash Flow6.90M9.33M14.47M4.96M715.20K66.35M

Cytosorbents Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.89
Price Trends
50DMA
1.06
Negative
100DMA
1.01
Negative
200DMA
1.00
Negative
Market Momentum
MACD
<0.01
Negative
RSI
41.39
Neutral
STOCH
41.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.89 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.06, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 41.39 is Neutral, neither overbought nor oversold. The STOCH value of 41.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Risk Analysis

Cytosorbents disclosed 39 risk factors in its most recent earnings report. Cytosorbents reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cytosorbents Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$95.34M12.385.00%0.29%-22.13%
60
Neutral
HK$19.34B4.28-1.43%3.28%13.32%-14.38%
58
Neutral
$52.61M48.68-1.62%3.30%-112.70%
57
Neutral
$80.80M-9.80%15.16%-39.18%
57
Neutral
$98.86M-77.26%-9.59%8.78%
51
Neutral
$103.88M-123.51%7.60%-0.78%
46
Neutral
$67.78M-68.84%-7.81%65.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTSO
Cytosorbents
0.89
-0.15
-14.42%
FONR
Fonar
15.12
-2.01
-11.73%
NSPR
InspireMD
2.45
-0.40
-14.04%
XTNT
Xtant Medical Holdings
0.61
-0.02
-3.17%
SRTS
Sensus Healthcare
3.24
-3.54
-52.21%
HYPR
Hyperfine
1.28
0.22
20.75%

Cytosorbents Corporate Events

Product-Related AnnouncementsLegal ProceedingsRegulatory Filings and Compliance
CytoSorbents Faces Regulatory Challenges for DrugSorb-ATR
Negative
Jul 2, 2025

On July 2, 2025, CytoSorbents Corporation announced regulatory updates regarding its DrugSorb-ATR device. The U.S. FDA scheduled an appeal hearing for the company’s supervisory review, while Health Canada issued a Notice of Refusal for the Medical Device License application due to non-compliance issues. CytoSorbents plans to address these concerns through the appeals process, aiming for final regulatory decisions by the end of 2025. The company believes DrugSorb-ATR offers a unique solution for reducing perioperative bleeding in cardiac surgery, addressing a critical need in the U.S. and Canadian markets.

Legal ProceedingsRegulatory Filings and Compliance
CytoSorbents Appeals FDA Denial of DrugSorb-ATR
Negative
Jun 24, 2025

On June 24, 2025, CytoSorbents Corporation announced its decision to appeal the U.S. FDA’s denial of its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding severity in patients undergoing coronary artery bypass grafting. The company filed for a supervisory review on June 18, 2025, aiming to resolve deficiencies identified by the FDA and believes a final regulatory decision can be achieved in 2025. The appeal process involves engaging with FDA senior leadership and external experts, reflecting CytoSorbents’ confidence in addressing the FDA’s concerns. Meanwhile, the DrugSorb-ATR application with Health Canada is under advanced review, with a decision expected in 2025 despite delays.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
CytoSorbents Confirms Director Elections at Annual Meeting
Neutral
Jun 13, 2025

CytoSorbents Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025, where stockholders voted on several key matters. The election of five directors was confirmed, the compensation of named executive officers was approved on a non-binding basis, and the appointment of WithumSmith+Brown, PC, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s ongoing governance and operational strategies, impacting its leadership structure and financial oversight.

Delistings and Listing Changes
Cytosorbents Announces Expiration of Series B Warrants
Negative
Jun 11, 2025

On June 11, 2025, CytoSorbents Corporation announced that the 5-day volume weighted average price per share of its common stock was below the required minimum of $2.00, leading to the expiration of the Series B Right Warrants issued in a prior Rights Offering. Consequently, payments made for the exercise of these warrants will be refunded without interest or penalty.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025